JP2021525105A5 - - Google Patents

Info

Publication number
JP2021525105A5
JP2021525105A5 JP2021516552A JP2021516552A JP2021525105A5 JP 2021525105 A5 JP2021525105 A5 JP 2021525105A5 JP 2021516552 A JP2021516552 A JP 2021516552A JP 2021516552 A JP2021516552 A JP 2021516552A JP 2021525105 A5 JP2021525105 A5 JP 2021525105A5
Authority
JP
Japan
Prior art keywords
bacteriophage
activity
lytic
target
crispr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021516552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525105A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034061 external-priority patent/WO2019227080A1/en
Publication of JP2021525105A publication Critical patent/JP2021525105A/ja
Publication of JP2021525105A5 publication Critical patent/JP2021525105A5/ja
Pending legal-status Critical Current

Links

JP2021516552A 2018-05-25 2019-05-24 標的細菌を死滅させるための方法および組成物 Pending JP2021525105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676818P 2018-05-25 2018-05-25
US62/676,818 2018-05-25
PCT/US2019/034061 WO2019227080A1 (en) 2018-05-25 2019-05-24 Methods and compositions for killing a target bacterium

Publications (2)

Publication Number Publication Date
JP2021525105A JP2021525105A (ja) 2021-09-24
JP2021525105A5 true JP2021525105A5 (enExample) 2022-05-26

Family

ID=68616480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516552A Pending JP2021525105A (ja) 2018-05-25 2019-05-24 標的細菌を死滅させるための方法および組成物

Country Status (4)

Country Link
US (1) US20210161150A1 (enExample)
EP (1) EP3817556A4 (enExample)
JP (1) JP2021525105A (enExample)
WO (1) WO2019227080A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
US20240011041A1 (en) * 2020-11-05 2024-01-11 Locus Biosciences, Inc. Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof
WO2022098899A1 (en) * 2020-11-05 2022-05-12 Locus Biosciences, Inc. Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof
CN117729853A (zh) * 2020-11-05 2024-03-19 洛可斯生物科学公司 包含crispr-cas系统的用于假单胞菌的噬菌体组合物及其使用方法
CN114854758B (zh) * 2022-06-14 2023-09-12 四川大学 基于CRISPR-Cas13a系统靶向杀死沙门氏菌的方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193314B2 (en) * 2007-07-12 2012-06-05 Massachusetts Institute Of Technology Transcriptional engineering of Lactobacillus
US10086018B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
EP4074330A1 (en) * 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
AU2015248621B2 (en) * 2014-04-14 2020-08-27 Nemesis Bioscience Ltd Therapeutic
WO2016177682A1 (en) * 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
WO2017015015A1 (en) * 2015-07-17 2017-01-26 Emory University Crispr-associated protein from francisella and uses related thereto
EP3426784A1 (en) * 2016-03-11 2019-01-16 Wageningen Universiteit Improved crispr-cpf1 genome editing tool
EP3429635B1 (en) * 2016-03-15 2026-05-06 University of Massachusetts Anti-crispr compounds and methods of use
US11845929B2 (en) * 2016-07-08 2023-12-19 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide RNAs, and uses thereof

Similar Documents

Publication Publication Date Title
Allen et al. Finding alternatives to antibiotics
Salmond et al. A century of the phage: past, present and future
Paul et al. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection
Jassim et al. Natural solution to antibiotic resistance: bacteriophages ‘The Living Drugs’
Olson et al. Application of bacteriophages to limit Campylobacter in poultry production
Born et al. Novel virulent and broad-host-range Erwinia amylovora bacteriophages reveal a high degree of mosaicism and a relationship to Enterobacteriaceae phages
Elbreki et al. Bacteriophages and their derivatives as biotherapeutic agents in disease prevention and treatment
García-Cruz et al. Myriad applications of bacteriophages beyond phage therapy
Doffkay et al. Bacteriophage therapy against plant, animal and human pathogens
JP2018518163A5 (enExample)
US11998579B2 (en) Immunogenic composition
JP2023548581A5 (enExample)
Li et al. Isolation and characterization of a novel Escherichia coli phage Kayfunavirus ZH4
Saunders et al. Phage‐mediated transfer of virulence genes
Anastassopoulou et al. Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules
US20180251787A1 (en) Crispr-cas10 systems and methods for phage genome editing
Pyzik et al. Experimental Phage Therapies in Companion Animals with A Historical Review
Pasharawipas et al. Phage treatment of Vibrio harveyi: a general concept of protection against bacterial infection
Gill et al. Bacteriophages and phage-derived products as antibacterial therapeutics
US20170333500A1 (en) Genetically Modified Bacteriophage (Bio-Phage)
Dias et al. The use of phage: therapy, biocontrol and commercial microbiology
Ruban et al. Bacteriophage: A Novel Biocontrol Agent Against Food Pathogens: Myth or Reality?
Anjali Promising Characteristics of Bacteriophage Endolysins in Food Preservation
Kasarla et al. Bacteriophage therapy: an alternative to antibiotics in the age of multi-drug resistance
Attama et al. Bacteriophage: Clinical Applications